Alex Rodriguez TRT: How His Biogenesis Scandal Shaped Patient Demand for Testosterone Therapy

Why the Rodriguez Case Became a Turning Point for TRT Awareness

Alex Rodriguez's 211-game suspension (later reduced to 162 games) announced in August 2013 was the largest in MLB history for PED violations. The Biogenesis of America clinic in Coral Gables, Florida allegedly supplied testosterone, human growth hormone, and other substances to Rodriguez and at least 12 other players. Because Rodriguez fought the suspension publicly and his lawyers repeatedly referenced "testosterone" by name in media filings, the word entered mainstream health conversations in a way that years of Low-T advertising had not achieved.

How Media Coverage Translated Into Clinic Traffic

When a celebrity's name appears alongside a drug in primetime news, search volume for that drug rises within days. A 2014 analysis published in the Journal of the American Medical Association found that direct-to-consumer pharmaceutical advertising increased physician visits for the advertised condition by roughly 16%, and celebrity health disclosures produced comparable or larger spikes in related health searches [1]. The Rodriguez coverage functioned, unintentionally, as mass advertising for testosterone awareness.

Telehealth and men's health clinic operators reported anecdotally that new patient inquiries included references to the MLB suspensions. Men who had never considered a testosterone level check began asking their primary care physicians about "TRT," often conflating therapeutic replacement with the supraphysiologic dosing associated with athletic doping.

The Critical Distinction: Replacement vs. Enhancement

Legitimate testosterone replacement therapy targets a serum total testosterone of 400 to 700 ng/dL, the mid-normal range for adult men, per the 2018 Endocrine Society Clinical Practice Guideline [2]. Athletes misusing testosterone for performance typically push levels to 1,000 to 2,500 ng/dL or higher, well outside any therapeutic window. The Endocrine Society guideline states: "We recommend against starting testosterone therapy in patients with the goal of improving athletic performance, fertility, or reversing age-related physiologic decline in the absence of a clinical syndrome of hypogonadism" [2].

That distinction matters clinically. Supraphysiologic testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, causes testicular atrophy, raises hematocrit to potentially thrombogenic levels, and adversely alters lipid profiles [3].

What Legitimate Hypogonadism Looks Like Clinically

Hypogonadism is not a lifestyle choice. It is a clinical syndrome with defined biochemical and symptomatic criteria. The Endocrine Society requires two fasting morning total testosterone measurements below 300 ng/dL, collected on separate days, before initiating therapy [2].

Symptom Criteria

Symptoms that support a hypogonadism diagnosis include decreased libido, erectile dysfunction, reduced muscle mass, increased adiposity, fatigue, depressed mood, and reduced bone mineral density. A 2006 population-based study by Mulligan et al. (N=2,162 men aged 45 and older) found that 38.7% had total testosterone levels below 300 ng/dL, yet only a subset had the full symptom cluster required for diagnosis [4]. Biochemical hypogonadism without symptoms does not automatically warrant treatment.

Laboratory Workup

A complete workup includes:

• Total testosterone (two morning draws, ideally before 10 a.m.)
• Sex hormone-binding globulin (SHBG) to calculate free testosterone
• LH and FSH to classify primary vs. Secondary hypogonadism
• Prolactin if secondary hypogonadism is suspected
• Hematocrit, PSA, and lipid panel as pre-treatment baselines

The FDA-approved labeling for testosterone products specifies that therapy should be reserved for men with "associated signs and symptoms" plus confirmed low serum testosterone [5].

Approved Formulations and Doses

The FDA has approved several testosterone formulations for male hypogonadism [5]:

• Testosterone cypionate injection: 100 to 200 mg IM every 1 to 2 weeks
• Testosterone enanthate injection: 50 to 400 mg IM every 2 to 4 weeks (titrated to response)
• Testosterone gel 1%: 50 mg (5 g) daily, titrated to 100 mg maximum
• Testosterone undecanoate (Aveed): 750 mg IM at weeks 0, 4, then every 10 weeks

None of these regimens is designed to produce the supraphysiologic peaks that characterize athletic doping.

The Biogenesis Clinic: What Was Actually Dispensed

Court records and MLB arbitration documents, publicly reported in detail by ESPN and the Miami New Times, described a menu of substances dispensed by Biogenesis founder Anthony Bosch. Testosterone was listed alongside human growth hormone (HGH), insulin-like growth factor-1 (IGF-1), and "troches" (compounded hormone lozenges). The testosterone forms reportedly included injectable testosterone and compounded testosterone cream.

Compounded Testosterone: A Regulatory Gray Zone

Compounded testosterone sits in a complex regulatory space. The FDA does not approve compounded medications but allows state-licensed pharmacies to prepare them under specific conditions [5]. Critics of "Low-T" clinics argue that compounding pharmacies enable prescribing of testosterone at doses and concentrations not available in commercial products, potentially facilitating misuse under the guise of personalized medicine.

A 2020 JAMA Internal Medicine study found that testosterone prescribing from compounding pharmacies increased 90-fold between 2001 and 2011, far outpacing the rise in diagnosed hypogonadism [6]. That disproportion suggests some prescribing reflected demand-side pressure rather than clinical indication.

WADA and Therapeutic Use Exemptions

The World Anti-Doping Agency (WADA) permits testosterone use in athletes with documented medical need through a Therapeutic Use Exemption (TUE). Requirements include confirmation of primary or secondary hypogonadism by an endocrinologist, with serum testosterone consistently below the lower limit of normal [7]. Rodriguez never applied for or received a TUE for testosterone, which reinforced the interpretation that his use was for performance enhancement rather than medical necessity.

How Celebrity PED Cases Change Patient Behavior

The Rodriguez story is one of several high-profile cases that reshaped public understanding of testosterone. Lance Armstrong's 2013 confession included testosterone and EPO use. Tiger Woods's 2009 media coverage referenced HGH and testosterone prescriptions. Each cycle of celebrity disclosure correlates with measurable short-term increases in patient queries and clinic visits related to the disclosed substance.

The "Informed Patient" Who Arrives With a Protocol in Mind

One practical consequence for prescribers: patients now arrive at consultations having researched specific protocols online. Forums such as Reddit's r/Testosterone (over 350,000 members) and r/steroids circulate detailed "TRT protocols" that reference celebrity cases as social proof. A patient citing Alex Rodriguez may be arriving with a pre-formed notion that 200 mg testosterone cypionate weekly is a standard medical dose, when in fact 200 mg weekly often produces supraphysiologic peaks.

A 2017 study in Clinical Endocrinology found that men who self-reported researching testosterone therapy online before a clinical visit were significantly more likely to arrive with expectations for a specific dose or formulation, and significantly less likely to accept a watchful-waiting recommendation when their total testosterone fell between 300 and 400 ng/dL [8].

What Clinicians Should Say

The Endocrine Society's 2018 guideline advises clinicians to "inform patients that TRT has not been established to improve vitality, energy, or physical function in men without hypogonadism" [2]. When a patient references a celebrity, the clinical response should:

1. Acknowledge the patient's interest without dismissing it.
2. Explain the difference between therapeutic serum targets and doping-level concentrations.
3. Order appropriate labs before any prescribing decision.
4. Discuss risks: polycythemia (hematocrit >54% warrants dose reduction or phlebotomy), cardiovascular signal (debated but present in older men with pre-existing disease), infertility from HPG axis suppression, and dermal transfer risk for partners or children using gel formulations.

Cardiovascular Risk: The Debate Prescribers Cannot Ignore

No discussion of TRT demand is complete without addressing the cardiovascular safety question, which became more prominent after the 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial was halted early. That trial (N=209) found a higher rate of cardiovascular events in testosterone-treated men vs. Placebo (23 vs. 5 events, P<0.001) [9]. The population was older (mean age 74) with substantial comorbidities, limiting generalizability.

The TRAVERSE Trial Changes the Evidence Base

The 2023 TRAVERSE trial (N=5,246 middle-aged and older hypogonadal men with elevated cardiovascular risk) found that testosterone replacement did not increase major adverse cardiovascular events (MACE) over a median follow-up of 33 months compared to placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [10]. The FDA reviewed TRAVERSE data and updated testosterone labeling in 2023 to reflect that cardiovascular risk in hypogonadal men treated to physiologic levels is not definitively elevated.

TRAVERSE did find higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm, signaling that the drug is not entirely risk-free even at therapeutic doses [10].

Polycythemia Monitoring

Testosterone stimulates erythropoiesis. A hematocrit above 54% requires dose reduction, formulation change, or therapeutic phlebotomy. The Endocrine Society recommends checking hematocrit at 3 and 6 months after initiation and annually thereafter [2]. Patients misusing testosterone at supraphysiologic doses face substantially higher erythrocytosis risk, with injectable forms producing sharper peak-to-trough hematocrit swings than gels [3].

TRT and Fertility: A Consequence Many Patients Do Not Anticipate

Exogenous testosterone suppresses LH and FSH via negative feedback on the HPG axis, effectively shutting down spermatogenesis. Azoospermia can develop within 3 to 4 months of starting TRT [11]. For men who have not yet completed their families, this is a decision-critical fact that celebrity narratives almost never communicate.

Alternatives for Hypogonadal Men Who Want to Preserve Fertility

Clomiphene citrate (50 mg every other day) stimulates endogenous LH and FSH production, raising testosterone without suppressing spermatogenesis. Human chorionic gonadotropin (hCG), dosed at 500 to 1,000 IU subcutaneously three times per week, can maintain intratesticular testosterone during TRT to partially preserve sperm production [11]. Neither of these options appears in the protocol sheets circulating on men's health forums inspired by celebrity cases.

The "Low-T" Industry and the Rodriguez Effect

Between 2000 and 2013, testosterone prescriptions in the United States increased more than 300%, according to data analyzed by Baillargeon et al. In a 2013 JAMA Internal Medicine study [6]. Direct-to-consumer advertising campaigns by brands such as AndroGel drove much of this increase. The Rodriguez case added a different kind of visibility: if a world-class athlete was using testosterone, men reasoned, surely it must confer benefits that their primary care doctors were not mentioning.

The prescribing surge eventually triggered regulatory action. In 2015, the FDA required manufacturers to add a label warning that cardiovascular risk had not been established and that testosterone was approved only for men with medical hypogonadism, not age-related testosterone decline [5]. The agency also required a new warning about venous thromboembolism risk.

Who Is Actually Getting Prescribed

A 2020 study in JAMA Internal Medicine (N=103,787 testosterone initiators) found that 25.2% of men starting TRT had no documented testosterone measurement in the prior year, and 40.1% had no documented low testosterone result [12]. Those numbers reflect a prescribing environment shaped as much by patient demand as by clinical indication, a dynamic that celebrity cases directly feed.

What a Responsible TRT Prescriber Does Differently

The gap between celebrity-inspired demand and evidence-based prescribing is wide but bridgeable. A responsible protocol includes pre-treatment labs (see Laboratory Workup section above), a trial period of 3 to 6 months with outcome reassessment, and discontinuation if no symptomatic benefit is documented.

The Endocrine Society recommends re-evaluating patients at 3 months, 6 months, and annually thereafter, checking total testosterone (trough level for injections, 2 to 8 hours post-application for gels), hematocrit, PSA, and bone density in men with osteoporosis [2]. If no improvement in the presenting symptoms is seen by 6 months, the guideline supports discontinuing therapy.

Patients who arrive citing Alex Rodriguez, Tiger Woods, or any other athlete need to hear clearly that the documented therapeutic target is 400 to 700 ng/dL total testosterone, not the supraphysiologic range that produces athletic enhancement. The risks change substantially above 1,000 ng/dL.